Half Year Report
January 1 – June 30, 2026

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease

Business highlights January – June 2026

- Reported positive Phase 1b biomarker data demonstrating a clear biological response to HER-096 in people with Parkinson's disease.

- Successfully completed a directed share issue raising EUR 4.2 million to support Phase 2 preparations and ongoing partnering discussions.

- Selected to lead a consortium that was awarded an EUR 8.0 million Horizon Europe 2025 Research and Innovation grant to support the execution of the planned Phase 2 trial of HER-096 in Parkinson's disease.

- Presented Phase 1b data for HER-096 at 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2026).

- Announced a collaboration to integrate Indivi's digital biomarker platform into the upcoming Phase 2 study of HER-096, aiming to detect early treatment-related changes in motor and cognitive function.

- Received positive feedback from a pre-IND meeting with the U.S. Food and Drug Administration (FDA), supporting the Company's option to pursue an Investigational New Drug (IND) application. An active IND for the planned Phase 2 study would provide external validation in the world's largest pharmaceutical market and increase HER-096's attractiveness in licensing discussions with global and U.S. partners.

- Appointed CTC Clinical Trial Consultants AB (CTC) as the clinical research organization (CRO) for the Phase 2 study.

- Appointed Dr Juha Savola as Chief Medical Officer, bringing more than 25 years of global experience in drug development, regulatory affairs and strategic leadership across neurology, gene therapy and rare diseases

Key figures:

EUR thousands	January - June		Full Year
	2026	2025	2025
Other operating income	0	135	178
Payroll and related expenses	1 170	1 115	1 921
Other operating expenses	1 893	1 975	4 652
Profit (loss) for the period	-3 324	-3 201	-6 620
Cash flow from operating activities	-3 332	-3 388	-6 095

	January - June		Full Year
	2026	2025	2025
Equity ratio	-0,20	0,34	-0,63
Basic and diluted profit (loss) per share EUR	-0,12	-0,13	-0,28
Number of shares at end of period	26 503 817	24 094 817	24 094 817
Average number of shares	25 872 751	23 173 741	23 634 279

EUR thousands	30.06.2026	30.06.2025	31.12.2025
Cash and securities[1)]	3 505	4 559	2 597
Equity	-796	1 749	-1 687
Balance sheet total	4 038	5 112	2 668

1) June 30-2026: Cash = 738' and Securities = 2 767' June 30-2025: Cash = 446' and Securities = 4 113'

Formulas used to calculate key figures:
Equity ratio = Equity/balance sheet total, Earnings per share = Profit for the period/average number of shares

Average number of shares = Weighted average number of shares.

The number of shares weighted by the number of days each share has been outstanding during the review period

Antti Vuolanto, CEO of Herantis Pharma, commented: *"The first half of 2026 has been highly productive for Herantis. We reported Phase 1b biomarker data confirming biological activity consistent with HER-096's proposed mechanism, secured important financing and non-dilutive funding, and received encouraging FDA feedback. Combined with the continued refinement of our Phase 2 study design and the appointment of Dr. Juha Savola as Chief Medical Officer, these achievements have further strengthened the scientific and strategic foundation of Herantis and enhanced our readiness for the next stage of development of HER-096. As we move through the remainder of the year, our focus remains on completing preparations for the Phase 2 study while continuing to evaluate opportunities to maximize the potential of HER-096 for patients and shareholders, including continued partnering discussions."*

About Herantis

Herantis Pharma is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease. The Company's lead product candidate, HER-096, is a first-in-class small peptide designed to harness the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF) while offering the convenience of subcutaneous administration. HER-096 targets key biological processes associated with neurodegeneration, including inflammation and protein misfolding, and has demonstrated effective brain penetration. It has the potential to slow or halt the

progression of Parkinson's disease, protect and restore neuronal function, and ultimately enhance patients' symptoms and quality of life. HER-096 is supported by more than 15 years of research, and the scientific approach has received validation and support from external organizations, including The Michael J. Fox Foundation, Parkinson's UK and the European Innovation Council. HER-096 has the potential to become the first disease-modifying treatment for Parkinson's disease.

Herantis Pharma was founded in Helsinki, Finland in 2008 and is listed at Nasdaq First North Helsinki marketplace with ticker HRTIS.

Review of operations

January 1 – June 30, 2026

The first half of 2026 was a period of significant strategic, clinical and operational progress for Herantis. Building on the positive safety, pharmacokinetic and biomarker data from the Phase 1b study, the Company focused on advancing preparations for the Phase 2 proof-of-concept efficacy study of HER-096.

Phase 1b Biomarker Data

In January, Herantis reported positive biomarker results from its Phase 1b trial of HER-096. Together with the positive safety, tolerability and pharmacokinetic results reported in October 2025, these findings completed the Phase 1b dataset.

Biomarker data demonstrated compelling evidence of a biological response to HER-096 in people with Parkinson's disease. These findings aligned with the expected mechanism of action and strongly support the advancement of HER-096 into further clinical development.

Key findings included:

- Consistent treatment-associated changes in biomarkers linked to proteostasis, mitochondrial function and neuroinflammation – key biological pathways associated with the unfolded protein response (UPR) and Parkinson's disease.
- Modulation of biological pathways directly relevant to HER-096's mechanism of action, with strong alignment between targeted and untargeted biomarker datasets and preclinical findings.

Together, the biomarker findings and previously reported clinical data provide a comprehensive Phase 1 data package supporting the advancement of HER-096 into Phase 2 clinical development. These Phase 1 results will inform dose selection, endpoint refinement and biomarker prioritization in future studies.

In March 2026, Herantis' Chief Scientific Officer, Henri Huttunen, presented the data at the AD/PD 2026 conference in an oral presentation. This marked the first public scientific presentation of the complete Phase 1b dataset.

Directed Share Issue

On February 11, 2026, Herantis successfully completed a EUR 4.2 million directed share issue. The financing included participation by the European Innovation Council (EIC) Fund under its existing commitment to invest up to EUR 15 million (of which EUR 10.8 million remains unutilized) in Herantis, providing further external validation of the Company's development strategy. The proceeds will

advance preparations for Phase 2, including chemistry, manufacturing and controls (CMC) activities, while strengthening the Company's position in ongoing financing and partnership discussions.

Horizon Europe Grant of EUR 8.0 Million

On February 19, 2026, Herantis announced that it had been selected to lead a consortium awarded a EUR 8.0 million grant under the Horizon Europe 2025 Research and Innovation program's *"Boosting the translation of biotech research into innovative health therapies"* initiative. The consortium brings together leading partners in clinical research, academia and industry from across Europe. The grant supports HERMOD (HER-096 Motor Outcomes and Disease Modification in Parkinson's Disease), a multinational research project established to evaluate HER-096 in a Phase 2 clinical trial in people with Parkinson's disease. Officially initiated in June 2026, the project seeks to generate robust clinical evidence advancing HER-096 as a potential disease-modifying treatment for Parkinson's disease. The selection of Herantis from a highly competitive field of innovative European companies provided further validation of the scientific rationale and development strategy for HER-096. The grant also represents an important source of non-dilutive funding for the planned Phase 2 study.

Phase 2 Study Preparations

During the period, Herantis made significant progress in preparations to initiate its Phase 2 proof-of-concept study of HER-096 in patients with early-stage Parkinson's disease.

The Company held a pre-IND meeting with the U.S. Food and Drug Administration (FDA) and received positive feedback on the development program. The FDA raised no concerns regarding the Company's chemistry, manufacturing and controls (CMC) information or preclinical data package and considered the planned Phase 2 study design appropriate for the current stage of development.

The randomized, double-blind, placebo-controlled Phase 2 study is expected to enroll approximately 100 patients with early-stage Parkinson's disease across multiple sites in Europe. The study is designed to evaluate initial efficacy, safety and tolerability of HER-096 and to generate the first proof-of-concept data on its disease-modifying potential.

The study design incorporates learnings from the Phase 1b program, including pharmacokinetic and biomarker findings, as well as feedback received through the interactions with scientific community and Health authorities. Herantis also appointed CTC Clinical Trial Consultants AB (CTC) as its clinical CRO to support study execution and operational preparations for trial initiation.

In May 2026, Herantis announced a collaboration with Indivi to integrate Indivi's digital biomarker technology into its upcoming Phase 2 Parkinson's disease trial. Designed to provide objective and continuous functional monitoring, the technology aims to capture early treatment-related changes with greater sensitivity than conventional clinical assessments.

Backed by an EUR 8.0 million Horizon Europe grant and potential investment from the EIC Fund, Herantis has a solid financial foundation for its Phase 2 study. The Company continues to pursue complementary financing, such as strategic partnerships, equity, and non-dilutive funding, to drive advancement into Phase 2.

Appointment of Chief Medical Officer

In June, Herantis appointed Dr Juha Savola, MD, PhD, as Chief Medical Officer (CMO). Dr Savola brings more than 25 years of international experience in drug development, regulatory affairs and leadership roles across neurology, gene therapy and rare diseases. He has previously held senior leadership positions at Spark Therapeutics, Teva Pharmaceuticals and Roche. His appointment further strengthens the Company's leadership team as Herantis advances HER-096 into Phase 2 development and continues its strategic partnering discussions.

About Parkinson's Disease

Parkinson's disease (PD) is characterized by chronic, progressive and debilitating neurological disorder affecting more than 10 million people worldwide, including 1.2 million in the EU. The disease is caused by the degeneration and loss of dopamine-producing neurons in the brain. The resulting reduction in dopamine levels leads to a range of motor symptoms including tremor, balance disturbances and falls, as well as non-motor symptoms such as cognitive decline, autonomic dysfunction and dementia. Despite decades of research, no disease-modifying therapies capable of slowing or stopping the progression of PD have been approved. Existing treatments address symptoms only, and their effectiveness diminishes over time.

The global market for Parkinson's disease therapeutics was estimated at USD 5.7 billion in 2024 and is projected to reach USD 11.6–13.3 billion by 2032–2034. A disease-modifying treatment capable of slowing or stopping disease progression would represent a transformational breakthrough for patients and a significant commercial opportunity.

Strategy

Herantis Pharma's strategy is to maximize shareholder value by advancing HER-096 through clinical development. Simultaneously, the Company is evaluating other development opportunities for HER-096, including strategic partnerships to support its further development and commercialization.

The Company remains engaged in discussions with potential biopharma partners and believes that the positive Phase 1b safety, pharmacokinetic and biomarker data, together with recent regulatory, clinical and financing milestones, have further strengthened HER-096's position as a differentiated partnering opportunity.

Beyond Parkinson's disease, the broad functionality of CDNF and HER-096's mechanism of action may offer potential across a range of neurodegenerative and neurological disorders, including ALS, Alzheimer's disease and stroke. These opportunities could support future indication expansion and further enhance the long-term value of the HER-096 program.

Outlook for 2026

The progress made during the first half of 2026 significantly strengthened the HER-096 program and advanced preparations for the planned Phase 2 proof-of-concept study. During the remainder of 2026, the Company will focus on completing activities required to initiate the Phase 2 study, including regulatory submissions, operational preparations and securing additional financing.

Herantis expects to initiate the Phase 2 study in the first half of 2027, with the first patient dosing to take place following completion of the remaining CMC activities and receipt of the necessary

regulatory approvals. In parallel, the Company will continue to pursue strategic partnering opportunities for the future development and commercialization of HER-096.

Employees, Management, Board of Directors, Scientific Advisory Board and Nomination Committee

During this reporting period, the Company's Board of Directors comprised Chairman Timo Veromaa, Hilde Furberg, Aki Prihti, Mats Thorén and Frans Wuite.

The number of employees at the end of the review period on June 30, 2026, was 14 (13), and the management team consisted of CEO Antti Vuolanto DSc, CSO Henri Huttunen PhD, CFO Tone Kvåle and CMO Juha Savola MD, PhD.

Herantis' Scientific Advisory Board (SAB) comprises four globally leading experts in the development of therapies for Parkinson's disease from industry and academia. The SAB members are Dr. Anders Gersel Pedersen (former EVP, R&D, Lundbeck), Dr. Daniele Bravi M.D. (former VP, Lundbeck), Prof. David Dexter, PhD (Imperial College, London) and Prof. Alberto Espay, M.D., MSc (Univ. of Cincinnati). The SAB is chaired by Dr. Pedersen.

Herantis' Shareholders' Nomination Committee consists of four members, of which three represent the Company's shareholders. The Chairman of Herantis' Board of Directors serves as the fourth member of the Nomination Committee. The Shareholders' Nomination Committee prepares and presents to the Annual General Meeting proposals on the remuneration, number and composition of the Board of Directors.

The following members have been appointed to Herantis' Shareholders' Nomination Committee: Kyösti Kakkonen, representing Joensuun Kauppa ja Kone Oy (Chairman), Petteri Vaarnanen, representing Säästöpankki Pienyhtiöt and Säästöpankki Kotimaa funds, Pia Gisgård, representing Swedbank Robur and Timo Veromaa, the Chairman of Herantis' Board of Directors.

Financial review

January 1 – June 30, 2026

(Figures in brackets = same period 2025 unless stated otherwise)

Accounting principles

Herantis prepares financial statements in accordance with Finnish Accounting Standards (FAS). This financial report is unaudited. The figures presented have been individually rounded from exact figures.

Statement of Profit & Loss

Herantis recorded no other operating income for the first half of 2026, compared to EUR 135 thousand in the same period last year. The EIC Accelerator project, ReTreatPD, was concluded as planned at the end of April 2025.

Both payroll-related expenses at EUR 1.2 million (EUR 1.1 million) and other operating expenses at EUR 1.9 million (EUR 2.0 million) remained stable year-on-year. R&D expenses for the first half of 2026 amounted to EUR 1.6 million (EUR 2.0 million) and were recognized in the income statement under other operating expenses and payroll-related expenses.

Net financial items totaled EUR -0.3 million (EUR -0.2 million). The finance income and expenses for 1H 2026 comprised of bank interest, gains from the disposal of short-term fixed-income securities, and expenses related to the February 2026 directed share issue, which raised EUR 4.2 million.

Herantis recognized a net loss of EUR 3.3 million for 1H 2026, compared to a net loss of EUR 3.2 million for 1H 2025.

Statement of Profit & Loss	January 1st - June 30st		Full Year
EUR thousands	2026	2025	2025
Revenue	**0**	**0**	**0**
Other operating income	0	135	178
Payroll and related expenses	1 170	1 115	1 921
Other operating expenses	1 893	1 975	4 652
Total operating expenses	3 063	3 090	6 573
Operating profit (loss)	**-3 063**	**-2 955**	**-6 395**
Finance income	7	18	30
Other financial income	29	62	102
Finance expenses	-298	-327	-357
Total finance income and expenses	-262	-247	-225
Profit (loss) before taxes	**-3 324**	**-3 201**	**-6 620**
Profit (loss) for the financial period	**-3 324**	**-3 201**	**-6 620**
Profit (loss)	**-3 324**	**-3 201**	**-6 620**
Profit (loss) per share, EUR	**-0,12**	**-0,13**	**-0,28**
Basic and diluted profit (loss) per share	-0,12	-0,13	-0,28

Statement of financial position (balance sheet)

As of June 30, 2026, Herantis total assets amounted to EUR 4.0 million, down from EUR 5.1 million as of June 30, 2025. Short-term debt increased by EUR 0.8 million, rising from EUR 0.6 million as of June 30, 2025, to EUR 1.4 million as of June 30, 2026. This increase was driven by preparatory activities for the Phase 2 clinical trial, including chemistry, manufacturing, and controls (CMC) work.

The balance sheet also includes long-term debt of EUR 3.4 million (up from EUR 2.7 million). This increase relates to research funding received from a consortium consisting of The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Parkinson's Virtual Biotech. This consortium has provided a total of EUR 3.6 million in research funding to finance Herantis Phase 1b clinical trial of HER-096 in Parkinson's disease, as well as its biomarker project. The funding is paid in cash over a two-year period upon completion of agreed milestones; the final installment of EUR 0.2 million is expected in 2026.

Repayment of the research funding will be triggered only if Herantis enters into a licensing or sublicensing agreement, HER-096 generates product sales, or there is a change of control of the Company or the intellectual property rights related to HER-096. Subject to the commercial success of HER-096, no more than 10% of the cash or non-cash consideration Herantis receives will be repaid to MJFF and Parkinson's Virtual Biotech until the total amount repaid reaches a maximum of four times

the research funding received. This research funding is classified as long-term debt in the balance sheet and the repayment obligation has been assessed as of June 30, 2026.

No R&D expenses were capitalized during the review period.

EUR thousands **Statement of financial position**	**January 1st - June 30st 2026**	**January 1st - June 30st 2025**	**December 31st 2025**
ASSETS			
Current assets			
Short-term			
Other debtors	120	153	37
Prepayments and accrued income	413	400	35
	533	553	72
Securities	2 767	4 113	1 846
Cash in hand and at banks	738	446	751
Total current assets	4 038	**5 112**	**2 668**
TOTAL ASSETS	**4 038**	**5 112**	**2 668**

Statement of financial position	**January 1st - June 30st 2026**	**January 1st - June 30st 2025**	**December 31st 2025**
EQUITY & LIABILITIES			
Capital and reserves			
Subscribed capital			
Subscribed capital	80	80	80
	80	80	80
Other reserves			
Free invested equity reserve	89 155	84 939	84 939
Retained loss	-86 707	-80 069	-80 087
Loss for the financial year	-3 324	-3 201	-6 620
Total equity	**-796**	**1 749**	**-1 687**
Debt			
Long-term			
Other liabilities	3 423	2 712	3 423
Loan from credit institutions	15	20	20
Total long-term debt	**3 438**	**2 732**	**3 443**
Short-term			
Loans from credit institutions	5	5	5
Trade creditors	581	282	389
Other creditors	49	48	31
Accruals and deferred income	760	296	487
Total short-term debt	**1 396**	**631**	**912**
Total liability	**4 834**	**3 363**	**4 356**
TOTAL EQUITY AND LIABILITIES	**4 038**	**5 112**	**2 668**

Cash flow statement

As of June 30, 2026, Herantis' cash and cash equivalents totaled EUR 738 thousand (EUR 446 thousand). In addition, the Company held EUR 2.8 million (EUR 4.1 million) in funds investing in euro-denominated, short-term fixed-income securities.

Cash flow from operations:

Cash flow from operating activities for the first half of 2026 was EUR -3.3 million (1H 2025: EUR -3.4 million).

Cash flow from investment:

During 1H 2026, Herantis received EUR 2.7 million (1H 2025: EUR 2.0 million) from the sale of short-term fixed-income securities. Additionally, the Company invested EUR 3.6 million (1H 2025: EUR 4.5 million) in a fund specializing in euro-denominated short-term fixed-income instruments.

Cash flow from financing:

In February 2026, Herantis raised EUR 4.2 million in gross proceeds through a directed share issue.

Statement of Cash flow	January - June		Full Year
EUR thousands	2026	2025	2025
Cash flow from operating activities:			
Profit (loss) before income taxes	-3 324	-3 201	-6 620
Adjustments:			
Other financial income and expenses	261	247	224
Cash flow before change in working capital	**-3 064**	**-2 955**	**-6 396**
Change in working capital:			
Increase(-)/decrease(+) in short term interest free receivables	-461	-117	365
Increase(+)/decrease(-) in short term interest free liabilities	483	-8	261
Cash flow from operations before financial items and taxes	**-3 042**	**-3 079**	**-5 769**
Interest paid and other financial expenses from operation	-298	-327	-357
Interest received and financial income from operation	7	18	30
Cash flow from operations before income taxes	-3 332	-3 388	-6 095
Cash flow from operating activities (A)	**-3 332**	**-3 388**	**-6 095**
Cash flow from investments:			
Investment in short-term fixed income securities	-3 593	-4 500	-4 500
Disposals of short-term fixed income securities	2 701	1 950	4 256
Cash flow from investments activities (B)	**-892**	**-2 550**	**-244**
Cash flow from financing:			
Gross proceeds from equity issue	4 216	5 193	5 193
Proceeds from long-term borrowings	0	556	1 268
Loan repayments	-5	0	-5
Cash flow from financing activities (C)	**4 211**	**5 749**	**6 456**
Change in cash and cash equivalents (A+B+C) incr. (+)/decr.(-)	-13	-189	116
Cash and cash equivalents at beginning of period	751	634	635
Cash and cash equivalents at end of period	**738**	**446**	**751**

Equity statement

As of June 30, 2026, equity stood at EUR -0.8 million compared to EUR 1.7 million as of June 30, 2025. Under the Finnish Limited Liability Companies Act (624/2006, as amended), a Company's board must file a register notification regarding the loss of share capital if the Company's equity becomes negative. However, if the fair value of the Company's assets is significantly and permanently higher than their book value, the difference between the estimated market price and the book value may be added to equity. The Board acknowledged that equity was negative as of June 30, 2026. Based on its assessment, the Board concluded that the fair value of the Company's intellectual property assets related to HER-096 is substantially higher than their book value. In the calculations required under the Limited Liability Companies Act, this valuation difference was therefore added to equity. Consequently, no register notification was filed.

Equity Statement Currency EUR	**January - June 2026**	**January - June 2025**
Restricted equity		
Share equity at the start of the period	80,000.00	80,000.00
Share equity at the end of the period	80,000.00	80,000.00
Restricted equity, total	**80,000.00**	**80,000.00**
Unrestricted equity		
Invested unrestricted equity reserve at the beginning of period	84,939,202.66	79,746,211.78
Issue of shares	4,215,750.00	5,192,990.88
Invested unrestricted equity reserve at the end of period	89,154,952.66	84,939,202.66
Loss from previous period, at the beginning of the period	-86,706,799.51	-80,069,152.12
Loss at the end of the previous period	-86,706,799.51	-80,069,152.12
Profit (loss) for the period	-3,324,211.94	- 3,201,437.04
Unrestricted equity, total	-876,058.79	1,668,613.50
Equity June 30	**-796,058.79**	**1,748,640.50**

Share-based incentive programs

Since Herantis prepares financial statements in accordance with Finnish Accounting Standards (FAS), stock options are not recorded as an expense in the statement of profit & loss.

Herantis has six stock option programs: 2021 I, 2022 I, 2023 I, 2024 I, 2025 I and 2026 I.

The Annual General Meeting (AGM) held on April 23, 2026, authorized the Board of Directors to issue up to 600,000 share options and shares, representing approximately two (2) percent of the Company's total issued shares. These options and special rights may be issued in one or several tranches.

On May 12, 2026, the Board of Directors of Herantis utilized this authorization to establish the new Option Rights Program 2026 I. Under this program, up to 600,000 option rights may be granted to the

CEO, management team, and key personnel. The issuance serves a compelling financial purpose: to align the long-term interests of key personnel with sustainable shareholder value creation.

The option rights will be granted free of charge. Each option entitles the holder to subscribe for one new ordinary share in Herantis. The share subscription price is set at 126% of the volume-weighted average price (VWAP) over the 10 trading days preceding the grant date. The granted options vest over a three-year period, with one-third (1/3) becoming exercisable each year on the anniversary of the grant date. The options expire five years from the grant date, subject to customary early termination conditions. Shares issued under the 2026 I program will not exceed 10% of the Company's outstanding shares at any time.

Stock option program	Subscription price per share	Maximum amount of option rights outstanding per June 30, 2026	Options exercised during 1H 2026	Options forfeited during 1H 2026	Options expired during 1H 2026	Subscription period
2021 I	3,44				546 454	April 2022 - April 2026
2021 I	2,60	150 000				April 2023 - April 2027
2022 I	2,49	50 000				September 2023 - September 2027
2022 I	2,21	145 000				December 2023 - December 2027
2023 I	2,45	300 000				June 2024 - June 2028
2024 I	2,05	400 000				July 2025 - July 2029
2025 I	1,75	600 000				May 2026 - July 2030
2026 I	2,24	600 000				May 2027 - July 2031
TOTAL		**2 245 000**	**0**	**0**	**546 454**	

Shareholder structure

At the end of the review period on June 30, 2026, Herantis' market capitalization stood at approximately EUR 48.7 million. The closing price of the Company's shares on the Nasdaq First North Growth Market Finland was EUR 1.84. During the review period, the share price reached a high of EUR 2.56, a low of EUR 1.58, and an average price of EUR 2.11. According to the shareholder register dated June 30, 2026, Herantis had 6,735 registered shareholders, representing a 58% increase from 4,262 shareholders at the end of June 2025.

Members of the Board of Directors and management held a total of 156,888 shares (compared to 154,388 previously), representing 0.6% (0.6%) of the Company's total shares. Information on managerial share transactions is disclosed via Company releases and on the corporate website.
One flagging notification was reported during 1H 2026 in accordance with Chapter 9, Section 10 of the Finnish Securities Markets Act. As of June 30, 2026, Herantis had a total of 26,503,817 shares. The Company has a single share class, with each share carrying one vote.

	Shareholders June 30, 2026	Numbers of shares	%
1	SKANDINAVISKA ENSKILDA BANKEN AB **(Nominee)**	3 930 613	14,8%
2	JOENSUUN KAUPPA JA KONE OY	2 472 973	9,3%
3	CITIBANK EUROPE PLC **(Nominee)**	1 094 680	4,1%
4	SIJOITUSRAHASTO SÄÄSTÖPANKKI PIENYHTIÖT	1 083 377	4,1%
5	PENSIONSFÖRSÄKRINGSAKTIEBOLAGET VERITAS	777 015	2,9%
6	KAKKONEN KARI HEIKKI ILMARI	742 757	2,8%
7	ILMARINEN MUTUAL PENSION INSURANCE COMPANY	684 857	2,6%
8	VARMA MUTUAL PENSION INSURANCE COMPANY	661 238	2,5%
9	HELSINGIN YLIOPISTON RAHASTOT	572 678	2,2%
10	LAAKKONEN MIKKO KALERVO	488 926	1,8%
11	KALONIEMI MARKKU PETTERI	447 105	1,7%
12	FENNIA LIFE INSURANCE COMPANY	391 083	1,5%
13	SIEMENTILA SUOKAS OY	343 514	1,3%
14	YLEISRADION ELÄKESÄÄTIÖ	329 025	1,2%
15	NORDEA NORDIC SMALL CAP FUND	326 280	1,2%
16	SUOTUULI OY	303 652	1,1%
17	K22 FINANCE OY	280 764	1,1%
18	SÄÄSTÖPANKKI KOTIMAA - SIJOITUSRAHASTO	251 030	0,9%
19	THE GROUP OY	227 958	0,9%
20	MÄKELÄ ARI MATTI	222 719	0,8%
	Top 20 largest shareholders	**15 632 244**	**59,0%**
	Others	**10 871 573**	**41,0%**
	Total numbers of shares	**26 503 817**	**100,0%**

Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders and constitutive meeting of the Board of Directors

Herantis Pharma Plc's (the "Company") Annual General Meeting was held in Helsinki on Thursday, April 23, 2026. The Annual General Meeting decided upon the following:

Adoption of the financial statements

The Annual General Meeting adopted the Company's financial statements for the financial year January 1– December 31, 2025.

Profit / loss for the financial year

The Annual General Meeting resolved, in accordance with the proposal by the Board of Directors, that no dividend will be paid for the financial year January 1 – December 31, 2025 and that the loss for the financial year shall be recorded in the profit and loss account.

Resolution on the discharge of the members of the Board of Directors and the CEO from liability for the financial year 2025

The Annual General Meeting resolved to grant discharge from liability to the persons acting as members of the Board of Directors and as the CEO of the Company.

Resolution on the remuneration of the members of the Board of Directors and reimbursement of travel expenses

The Annual General Meeting resolved, in accordance with the proposal by the Shareholders' Nomination Committee, that the remuneration of the Board of Directors shall be as follows:

- The remuneration payable to the members of the Board of Directors shall be EUR 19,000 annually for each member of the Board except for the Chair of the Board who shall be paid EUR 38,000 annually.

- The Chair of the Audit Committee shall receive a fixed annual fee of EUR 8,000 and each member of the Audit Committee a fixed annual fee of EUR 4,000.
- The Chair of the Remuneration Committee shall receive a fixed annual fee of EUR 4,000 and each member of the Remuneration Committee a fixed annual fee of EUR 2,000.

Board members are also reimbursed reasonable travel expenses related to the duties of the Board of Directors. The remuneration remains unchanged from the previous year.

Resolution on the number of the members and election of the members of the Board of Directors
In accordance with the proposal of the Shareholders' Nomination Committee, the Annual General Meeting resolved that the number of members of the Board of Directors shall be five (5).

In accordance with the proposal of the Shareholders' Nomination Committee, all current members of the Board of Directors, i.e., Timo Veromaa, Mats Thorén, Frans Wuite, Aki Prihti, and Hilde Furberg were re-elected as members of the Board of Directors.

Resolution on the remuneration of the Auditor
The Annual General Meeting resolved, in accordance with the proposal by the Board of Directors, that the Auditor be paid reasonable remuneration in accordance with the invoice approved by the Company.

Election of the Auditor
The Annual General Meeting resolved, in accordance with the proposal by the Board of Directors, to re-elect the firm of authorised public accountants PricewaterhouseCoopers Oy as the Company's auditor for a term ending at the end of the Company's next Annual General Meeting. PricewaterhouseCoopers Oy has notified the Company that APA Jonna Fabian will act as the principally responsible auditor.

Authorisation of the Board of Directors to decide on the issuance of shares
The Annual General Meeting resolved to authorise the Board of Directors to decide on the issuance of shares as follows:

The shares issued under the authorisation may be new shares or treasury shares. Under the authorisation, a maximum of 2,650,000 shares may be issued which corresponds to approximately 10 per cent of all the shares issued by the Company. The shares may be issued in one or more tranches.

The Board of Directors was authorised to resolve on all other terms and conditions of the share issue. The share issue may be directed, i.e., deviate from the pre-emptive subscription right of shareholders, provided that there is a weighty financial reason thereto.

The authorisation does not invalidate any earlier authorisations entitling the Board of Directors to decide on share issues or issues of special rights entitling to shares. The authorisation is valid until the close of the next Annual General Meeting, however no longer than until 30 June 2027.

Authorisation of the Board of Directors to decide on issuing option rights

The Annual General Meeting resolved to authorise the Board of Directors to resolve on issues of option rights pursuant to Chapter 10 of the Companies Act as follows:

A maximum of 600,000 share options and shares may be issued under the authorisation which corresponds to approximately two (2) per cent of all the shares issued by the Company. Option rights and other special rights entitling to shares may be issued in one or more tranches.

The option rights that may be issued under this authorisation along with previously issued option rights outstanding as of the date of the Annual General Meeting, will in aggregate entitle the option holders to subscribe for no more than 2,245,000 shares, corresponding to approximately eight (8) per cent of all the shares issued by the Company calculated on a fully diluted basis (i.e., the number of outstanding shares in the Company if all the abovementioned option rights were used to subscribe for shares).

Objective

The objective of the authorisation is to ensure that the employee option incentive program of the Company is aligned with international industry practices and thereby enables the Board to commit the existing and potential new key personnel into long-term value creation of the Company.

Eligibility

New employees are eligible for option grants upon joining the Company. Employees will be eligible for an annual option award on a discretionary basis, taking into account overall performance, competitiveness of terms, work responsibility, importance of retention, organisation level, and position. The Board of Directors will exercise discretion as to who will receive an equity award in any given year, based on recommendations made by the Remuneration Committee. The Board of Directors intends to grant awards under the plan on an annual basis. Board members are not eligible to participate.

Grant size and subscription price

The Remuneration Committee shall recommend to the Board the size of the overall option grant. The grant schedule will be determined, and reviewed, on the basis of market competitiveness of the equity component of the compensation package and the overall size of the available option and share pool approved by shareholders. The exercise price will correspond to 126 per cent of the volume weighted average share price of the Company's share during 10 trading days preceding the grant date. However, in no event shall the exercise price be lower than the subscription price of the Company's share in the Company's latest share issue against consideration (excluding share subscriptions based on option rights) preceding the option grant date.

Employee vesting schedule

Granted share options shall vest and become exercisable over a three-year period, with 1/3 on the first anniversary of the grant date, with an annual vesting of 1/3 during the second year after the grant date, and with an annual vesting of 1/3 during the third year after the grant date. The options expire five years

after the grant date. In the case of termination of employment, the employee will not vest further share options beyond notice of termination. Unless special circumstances dictate otherwise, the terminated employee can, as a general rule, exercise vested options no later than the expiry of the first

exercise period following the notice of termination (unless a later date has been resolved by the Board). Options not exercised prior to the above deadline will lapse.

The Board of Directors was authorised to resolve on all terms for the issuance of special rights entitling to shares. The granting of special rights entitling to shares may be directed, i.e., deviate from the pre-emptive subscription right of shareholders, provided that there is a weighty financial reason thereto.

The authorisation does not invalidate any earlier authorisations entitling the Board of Directors to decide on issues of special rights entitling to shares. The authorisation is valid until the close of the next Annual General Meeting, however no longer than until 30 June 2027.

Decisions of the constitutive meeting of the Board of Directors
In its constitutive meeting held after the Annual General Meeting, the Board of Directors elected Timo Veromaa as Chair of the Board. The Board of Directors also resolved on the composition of the Board Committees in its constitutive meeting.

Aki Prihti was elected as the Chair, and Mats Thorén and Hilde Furberg were elected as members of the Audit Committee. Timo Veromaa was elected as the Chair and Frans Wuite was elected as member of the Remuneration Committee.

Risk and uncertainties

Herantis is clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease and has or will have assets in preclinical and clinical development.

Key risk factors:

- The Company's products and business operations are at the research and development stage, and the Company may fail to reach profitability.
- The Company may face difficulties in obtaining further financing on competitive terms and conditions, or at all, and this may affect the continuity of the Company's operations.
- The Company's strategy is the development of new pharmaceutical products, which involves a lengthy and expensive process with uncertain outcomes.
- As Herantis advances the HER-096 program into the Phase 2 clinical study, the Company may face risks related to patient recruitment and retention, which could result in delays to study timelines and increased development costs.
- The business of Herantis is highly dependent on the success of its current or potential future drug candidates, which will require significant high-risk product development.
- Uncertain macroeconomic and financial market conditions as well as the geopolitical situation could have a material adverse effect on Herantis.
- Cybercrime targeting businesses has been steadily increasing over several years, particularly in critical sectors such as healthcare. Despite the implementation of security measures, the Company may still be vulnerable to cyberattacks.
- Herantis is exposed to the risks associated with operating in a highly competitive industry.
- Herantis is exposed to the risk of relying on third parties for preclinical projects, clinical trials and manufacturing.

- The Company may be unsuccessful in protecting or enforcing its intellectual property rights.
- Herantis may not be able to enter into or maintain partnership agreements.
- Due to the novelty of Herantis' drug candidate, HER-096, the risks associated with its development, or with the development of any other novel drug candidates Herantis may have in the future, can be considered greater than the risks typically associated with drug development and therefore also apply to the Company's operations.
- The Company's insurance coverage may prove insufficient, and its business involves the risk of liability claims in the event that the use or misuse of Herantis' current or potential future drug candidates results in injury or death.

General risks and uncertainties inherent in drug development also apply to Herantis. For instance, the production, stability, safety, efficacy, and regulatory aspects of drug candidates involve risks, the realization of which could make the commercialization of the drug candidate impossible or significantly delay it. One common challenge in drug development is that preclinical disease models may not accurately simulate the real disease. Promising preclinical results therefore do not guarantee that the drug candidate is efficacious in humans. Further, the Company has not commercialized any drug candidates, does not have any history of profitable operations, and has not to date entered into any commercialization agreements pursuant to its strategy.

Drug development requires significant investments. Since Herantis is a pre-revenue company, it must finance its drug development programs from external sources such as grants, R&D funding, loans, or equity investments from investors and existing shareholders. Factors such as delays in the Company's development programs, lack of share authorization, or a weak financial market can impact the Company's ability to raise funding and continue its operations. Even if the safety and efficacy of a drug candidate were established in clinical studies, its commercialization would involve risks such as pricing and reimbursement, organizing a sales network, competition from other emerging treatments, unexpected adverse events in long-term use, the strength of the Company's patents, patent infringement claims brought against the Company and other factors. The Company's success, competitive position, and future revenues will depend in part on the Company's ability to protect intellectual property and know-how. Competitors may claim that one or more of the Company's product candidates infringe their patents or other intellectual property.

Resolving a patent or other intellectual property infringement claim can be costly and time-consuming and may require the Company to enter into royalty or licensing agreements. The Company cannot guarantee that it would be possible to enter into such agreements on commercially advantageous terms or at all.

General business risks and uncertainties are also relevant to the operations of Herantis, such as data protection risks, dependencies on subcontractors and other third parties, and the ability to recruit and retain qualified senior team and other employees.

Herantis' strategy is to continuously identify, minimize and mitigate potential risks, and risk assessment and management are integral parts of Herantis' operations. Herantis has protected its operations against risks to the best of its ability and is not aware of any such risks or uncertainties that would essentially differ from the usual risks and uncertainties in its business.

Going concern

The Company has conducted a going concern review in accordance with Finnish Accounting Standards (FAS), and this unaudited financial report has been prepared on a going concern basis.

In February 2026, Herantis successfully completed a directed share issue, raising gross proceeds of EUR 4.2 million. The Company has prepared detailed financial and cash flow forecasts, looking beyond 12 months from June 30, 2026. These forecasts incorporate the EUR 4.2 million raised in February and reflect management's assumptions regarding current and expected future economic conditions. Based on these projections, current cash reserves are estimated to be sufficient to fund the chemistry, manufacturing, and controls (CMC) work, as well as clinical preparations for the Phase 2 clinical trial.

Additionally, on February 19, 2026, Herantis announced that it is leading a consortium selected for a EUR 8.0 million Horizon Europe 2025 grant, which will partially finance the Phase 2 trial of HER-096. This builds on the EIC's July 2023 approval of Herantis' application for a direct equity investment. Under this agreement, Herantis is eligible for up to EUR 15 million in direct equity investments from the EIC Fund. The EIC Fund can potentially match up to one-third of the aggregate capital raised in future financing rounds. As of June 2026, the EIC Fund has invested EUR 4.2 million of this total allocation. Given this strong commitment, the Company believes it can secure the necessary cash inflows to sustain its activities.

However, because future funding is not yet contractually committed and existing cash reserves only provide runway until end of 1H 2027, these circumstances indicate the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. Herantis will require additional capital to launch the Phase 2 clinical trial and is actively exploring strategic options to secure these resources. These options include development partnerships, equity financing, and non-dilutive funding.

Environmental factors

Herantis seeks to reduce its environmental impact and aims to operate without polluting the environment. All production and distribution activities are outsourced. Herantis' quality instructions and operating practices take environmental considerations into account, for example by encouraging the use of public transportation, limiting travel to essential business needs, and promoting virtual meetings where possible. Printing and waste are minimized, and recycling practices are applied where applicable.

Financial information

These financial statements release, and its appendices are published in Finnish and in English on August 20, 2026, at 8:00 EEST/7:00 CEST on the Company's website at www.herantis.com. In case of any discrepancies between the language versions, the Finnish version shall prevail.

Certified Advisor:

UB Corporate Finance Oy, Finland
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi

Financial calendar:

1H 2026 reporting: August 20, 2026

Investor contact:

Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com

Company website:

www.herantis.com

Forward-looking statements

This Company release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis' future financial position and results of operations, the Company's strategy, objectives, future developments in the markets in which the Company participates or is seeking to participate or anticipated regulatory changes in the markets in which the Company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should" or "will" or the negative of such terms or other comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future.

Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The Company's actual results of operations, including the Company's financial condition and liquidity and the development of the industry in which the Company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this Company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis' strategy, risks and uncertainties associated with the development and/or approval of Herantis' drug candidates, ongoing and future clinical trials, expected trial results, the ability to commercialize drug candidates, technology changes, new products in Herantis' potential market and industry, Herantis' freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors' patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. In addition, even if Herantis' historical results of operations, including the Company's financial condition and liquidity and the development of the industry in which the Company operates, are consistent with the forward-looking statements contained in this Company release, those results or developments may not be indicative of results or developments in subsequent periods.